Edema News and Research

RSS
Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.
Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

Basaglar (insulin glargine injection) approved to improve glycemic control in diabetes patients

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC

Harvard's Kevin Staley honored with AES Research Recognition Award for Basic Science

Harvard's Kevin Staley honored with AES Research Recognition Award for Basic Science

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Ninlaro (ixazomib) approved to treat people with multiple myeloma

New study reveals better treatment options for proliferative diabetic retinopathy

New study reveals better treatment options for proliferative diabetic retinopathy

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Pathophysiological biomarkers predict PAH prognosis

Pathophysiological biomarkers predict PAH prognosis

Vanderbilt study could lead to development of new drugs that relieve pain without causing vascular effects

Vanderbilt study could lead to development of new drugs that relieve pain without causing vascular effects

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

Patients experience improvements in joint specific pain and function after weight-loss surgery

Patients experience improvements in joint specific pain and function after weight-loss surgery

Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

Mallinckrodt announces approval of INOmax for cardiovascular surgery in Australia and Japan

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

Breakthrough research suggests that female sex hormone may save lives on the battlefield

Breakthrough research suggests that female sex hormone may save lives on the battlefield

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

Allergan completes acquisition of AqueSys

Allergan completes acquisition of AqueSys

First-in-human compassionate use cases with Edwards' FORMA transcatheter tricuspid repair system presented at TCT

First-in-human compassionate use cases with Edwards' FORMA transcatheter tricuspid repair system presented at TCT

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial